ExAblate (R) family systems employs the Ultrasound non invasively
heat and destroy the targeted tissue MR control. MRI-the most advanced imaging modality system available today, identify and objectives of the tumours, but in real time temperature monitoring of the treated tissue.
Experience substances of more than 6000 patients over 80 work centers around the world ExAblate family systems offers the proven commercially approved treatments and mature forum and clinical data on a wide variety of research settings.
Innovative ExAblate (R) one to extend the treatment choices for women suffering from rotissa poor and adenomyosis.Recent ExAblate (R) technical progress now large and vascular poor and adenomyosis, expanding patient base. The ability to handle larger volumes are expected to lead to greater fibroid clinical efficacy. ExAblate (R) significantly improve adenomyosis signs, and in many cases, improve the patient's ability to overcome infertility caused by the condition.
Patients on mature rotissa poor or generally return to their normal routine adenomyosis procedure a major improvement over most fibroid treatment techniques within 24 hours. the growing number of Women has become pregnant after exposure ExAblate. studies have shown that can even improve the MRgFUS suffering from infertility caused by rotissa poor fertility. (1)
Places around the world experience has shown that the ExAblate MRgFUS increase significantly in the interest of the patient handling and transport of the port facility.Tokyo, Japan's leading site reported that the number of patients treated rotissa poor increased by 550%.(2)
ExAblate treatment has also proven cost-efficient as an alternative to the current treatments, meeting the criteria for acceptable value fibroid treatment.(3)
"MR guided relating to the use of Ultrasound (MRgFUS) has been in the treatment of the poor rotissa approved and viable option in order to increase the number of women for several years. However, the ExAblate (R) with one of the improvements offered by we can provide a more effective, more women to women's health forum is liable for imminent damage which is a fixed result for treatment alternative. "Said the head of the Professor Wladyslaw M Gedroyc, MD, radiology, St. Mary's Hospital, London, United Kingdom. " The maintenance of patients, such as the uterus and the better chance of fertility in addition to the benefits we have seen a significant reduction in the handling of the case. "
ExAblate (R) or the environment is non-invasive image Guided and Controlled Acoustic Operating System will be repeated for each room. convertible cribs with one common shown in the table below.ExAblate (R), or offer commercially accepted and research processing settings across a wide range of clinical data, such as: rotissa poor and adenomyosis, breast cancer, prostate cancer, pain palliation of bone metastases, and other characters.
One of the ExAblate (r) and the ExAblate (R) or compatible with GE Healthcare Signa and product Discovery MRI lines and has just designed ergonomic benefit patients bed, a streamlined interface, and improved usability of doctors.
"Our vision is dedicated to the ExAblate system that offers a truly non-invasive treatment, extended selection and is addressed to the safety profile. ExAblate (R) 2000 in 2004, after the introduction of market researchers, clinical and must continue to further improve and enhance innovation and accumulating compensated clinical information and knowledge," said Dr. Kobi Vortman, President and CEO, InSightec. "We control system based on the Mr Ultrasound technology only provider to offer such good and mature picture Wizard and ambient acoustic surgery".
New ExAblate (R) 1 and ExAblate (R) or patients ' bed featured InSightec booth # 44 CIRSE (2-6, October 2010, Valencia, Spain) is also hosting at. InSightec Satellite symposium, CIRSE October 3rd at the address where the senior researchers will discuss their work in the different areas of ExAblate system.For more information about InSightec is intended to serve CIRSE please visit: http://www.insightec.com
1 Rabinovici J, M, H, K, Gostout BS, Stewart EA Morita Fukunishi MRgFUS Study Group David.The results of Magnetic Resonance-guided Pregnancy active Ultrasound Surgery (MRgFUS) for the conservative treatment of the poor, fertility & rotissa sterility, 2008.
2 Yutaka Nakamura Tetsuya Morita (R) the imposition of ExAblate 2000 Add income OB/GYN Department year InSightec clinical report vol. 2, no 1
3 O'Sullivan AK, Thompson (d), Chu P, Lee DW Stewart EA Weinstein MC. cost-effectiveness of Magnetic Resonance guided ultrasound treatment as well as the poor, health rotissa, 2009 in Technology Assessment J Int. 25: 14-25
About ExAblate (R)
ExAblate (R) one and must be constructed in such a way as to improvements to research, development and dedication to InSightec has unparalleled experience and innovation with the clinical examination doctors around the world.
ExAblate ® 2000 received the CE marking in 2002 and 2004 rotissa poor treatment of the Food and Drug Administration (FDA) approval system received in June 2007, bone metastases pain palliation and adenomyosis June 2010 the European CE marking. ExAblate 2000 has won numerous innovation awards and has been used to treat thousands of patients from around the world.
About InSightec
InSightec Ltd. is a privately held company owned by Elbit Imaging, General Electric, MediTech advisors, LLC and employees., it was created in 1999 to develop breakthrough technological MR controls access to the Ultrasound and convert the next generation of operating systems in the room. Haifa, Israel, close to the Head Office of the company has more than 160 employees and has invested in more than 130 million euro to research, development and clinical trials. United States seat Dallas, Texas. [1] [2] for more information, go to: http://www.insightec.com/
Note to editors:
ExAblate (R) One received the CE marking for management of June 2010, adenomyosis. It has been approved by the FDA.
Media contact: for more information, please contact: Dr. Jane Waggener Edstrom Brearley World Tower House 10 Southampton Street Pancras London WC2E 7HA Email: jbrearley@waggeneredstrom.com phone: + 44 (0) 20 7632-3800SOURCE InSightec Ltd
Back to the beginning of the
